Prime Medicine shares rise after FDA approves clinical trial application for gene-editing therapy
Prime Medicine's stock rose by 8% on Friday following the U.S. Food and Drug Administration’s (FDA) approval of its Investigational New Drug (IND) application for PM647, an experimental gene-editing treatment targeting Alpha-1 Antitrypsin Deficiency. The FDA clearance enables Prime Medicine to initiate a Phase 1/2 clinical trial to evaluate the safety and efficacy of PM647. This marks a significant milestone in the company’s pipeline development for genetic therapies using its proprietary PRIME editing platform, which aims to correct DNA mutations at the root cause level. Investors responded positively to the regulatory progress, reflecting optimism about Prime Medicine's potential to advance innovative gene-editing treatments and expand into new therapeutic areas.
Tickers: $PRME
Topics: biotech clinical trials gene-editing